Arcturus Therapeutics Holdings (ARCT) Asset Utilization Ratio (2019 - 2026)
Arcturus Therapeutics Holdings' (ARCT) quarterly Asset Utilization Ratio came in at 0.21 in Q1 2026, down 50.18% YoY from 0.43 in Q1 2025, and down 28.54% on a QoQ basis from 0.3 in Q4 2025.
Analysis
Arcturus Therapeutics Holdings (ARCT) Asset Utilization Ratio (2019 - 2026) Analysis & Trends
Arcturus Therapeutics Holdings (ARCT) has 8 years of Asset Utilization Ratio data on file, last reported at 0.21 in Q1 2026.
- Quarterly Asset Utilization Ratio fell 50.18% year-over-year to 0.21 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.21 (down 50.18% YoY) and the FY2025 annual result came in at 0.27, down 32.29% from the prior year.
- Asset Utilization Ratio retreated to 0.21 in Q1 2026, from 0.3 in the prior quarter.
- In the past five years, Asset Utilization Ratio ranged from a high of 0.67 in Q3 2023 to a low of 0.04 in Q1 2022.
- A 5-year average of 0.37 and a median of 0.38 in 2025 frame the typical range for Asset Utilization Ratio.
- Annual changes were most pronounced in 2022 — Asset Utilization Ratio soared 1753.49% — and 2024, when it sank 51.88%.
- Tracing ARCT's Asset Utilization Ratio over 5 years: stood at 0.55 in 2022, then tumbled by 32.09% to 0.38 in 2023, then gained by 13.33% to 0.43 in 2024, then slumped by 30.45% to 0.3 in 2025, then slipped by 28.54% to 0.21 in 2026.
- The last three Asset Utilization Ratio figures came in at 0.21 (Q1 2026), 0.3 (Q4 2025), and 0.33 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 0.47 |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 0.38 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 0.20 |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 0.69 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 0.90 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 0.13 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 0.54 |
| 10 | Arcturus Therapeutics Holdings | 449.65 Mn | 258.17 Mn | - | 0.13 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 0.13 |
| Mar 31, 2026 | 0.21 |
| Dec 31, 2025 | 0.30 |
| Sep 30, 2025 | 0.33 |
| Jun 30, 2025 | 0.38 |
| Mar 31, 2025 | 0.43 |
| Dec 31, 2024 | 0.43 |
| Sep 30, 2024 | 0.42 |
| Jun 30, 2024 | 0.41 |
| Mar 31, 2024 | 0.29 |
| Dec 31, 2023 | 0.38 |
| Sep 30, 2023 | 0.67 |
| Jun 30, 2023 | 0.59 |
| Mar 31, 2023 | 0.61 |
| Dec 31, 2022 | 0.55 |
| Sep 30, 2022 | 0.16 |
| Jun 30, 2022 | 0.12 |
| Mar 31, 2022 | 0.04 |
| Dec 31, 2021 | 0.03 |
| Sep 30, 2021 | 0.02 |